Related Experiment Videos
Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells
J Martin1, S Navas, J A Quiroga
1Unidad de Hepatologia, Fundacion Jimenez Diaz, Madrid, Spain.
Insights
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) reduced hepatitis C virus (HCV) RNA in infected cells. This antiviral effect was linked to increased interleukin-6 release but not other cytokines.
Area of Science:
- Virology
- Immunology
- Hematology
Background:
- Hepatitis C virus (HCV) infects mononuclear leukocytes in chronic hepatitis C patients.
- Understanding cellular responses to antiviral treatments is crucial for managing chronic infections.
Purpose of the Study:
- To investigate the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on HCV replication in infected peripheral blood mononuclear cells (PBMCs).
- To explore the relationship between rhG-CSF treatment, viral load reduction, and cytokine production in HCV-infected PBMCs.
Main Methods:
- Culturing mitogen-stimulated, naturally HCV-infected PBMCs from chronic hepatitis C patients.
- Treating cultures with varying doses of rhG-CSF.
- Quantifying genomic and antigenomic HCV RNA levels.
- Measuring the release of various cytokines, including interleukin-6.
Main Results:
- rhG-CSF demonstrated a dose-related reduction in both genomic and antigenomic HCV RNA strands.
- HCV genomic strand (subtype 1b) suppression occurred in 5 of 11 cases, with concurrent antigenomic strand suppression in two.
- A significant increase in interleukin-6 release was observed, but not other measured cytokines.
- The antiviral response to rhG-CSF was independent of specific cytokine production patterns.
Conclusions:
- rhG-CSF exhibits direct antiviral activity against Hepatitis C virus in infected human PBMCs.
- Interleukin-6 may play a role in the antiviral mechanism of rhG-CSF, although the overall response is complex and not solely cytokine-driven.
Abstract:
Hepatitis C virus infects mononuclear leukocytes of patients with chronic hepatitis C. Treatment with rhG-CSF led to a dose-related reduction in the genomic and antigenomic hepatitis C viral strands in cultures of mitogen-stimulated, naturally-infected peripheral blood mononuclear cells from patients with chronic hepatitis C. Hepatitis C virus genomic strand of subtype 1b was suppressed in 5 of 11 cases, and concurrently with suppression of the viral antigenomic strand in two of them. The treatment also resulted in a significantly increased release of interleukin 6, but not of other cytokines. However, the biological response of hepatitis C virus-infected mononuclear cells to treatment with recombinant human granulocyte colony-stimulating factor was unrelated to any particular pattern of cytokine production.